PharmaTell seminar: Long-circulating liposomes to reduce drug irritation in chemotherapy Event as iCalendar

26 February 2014

12 - 1pm

Venue: Room 505-364, Building 505, 85 Park Road, Grafton

Liposomes are established carriers for anticancer drugs due to their potential to target solid tumours and reduced toxicity by exploiting the enhanced permeability and retention (EPR) effect. From a practical standpoint, controlled drug release and high drug loading are vital to improve the therapeutic index, however, have posed challenges to the formulation scientists. Asulacrine (ASL) is an inhibitor of topoisomerase II, synthesized by Auckland Cancer Society Research Centre. It is an analogue of the anti-leukaemia drug amsacrine and has a broader antitumour spectrum. Although ASL showed promising data in clinical anticancer therapy such as breast and lung cancer, infusion thrombophlebitis (ITP) was well recognized as a significant complication with a high incidence of 53%.

Liposomes as a biomimic drug delivery system are envisioned to be able to separate the encapsulated drugs from the surrounding tissue fluid and prevent drug precipitation by controlled release, resulting in little damage of the vein. In this New Zealand/China Research Alliance Project, the irritation evaluation using different animal models and strategies to improve drug loading and retention in liposomal systems has been studied.

Presented by: Dr Wenli Zhang

Dr Wenli Zhang has finished her PhD study in China Pharmaceutical University in 2011. She researched high density lipoproteins as a nano-drug carrier for atherosclerosis therapy during PhD. Now she is a lecturer there. She joined the Auckland School of Pharmacy as a research fellow working on a New Zealand/China Research Alliance Project since December, 2013.


For further information please contact: School of Pharmacy Administration Phone:+64 9 373 7599 ext 82851 Fax: +64 9 367 7192 Email: enquiries@auckland.ac.nz